Novartis sues US government over Medicare drug price regulation Ruchika Sharma4 Sept 2023 11:31 AM ISTThe pharmaceutical industry says the program will curtail profits and compel it to pull back on developing new treatments.
Bristol Myers Squibb gets USFDA nod for Reblozyl as first line treatment of Anemia in lower risk MDS Ruchika Sharma29 Aug 2023 11:09 AM ISTReblozyl, a first-in-class therapeutic option, promotes late-stage red blood cell maturation in animal models.
Bristol Myers Squibb gets European Commission nod for Opdivo as adjuvant treatment for patients with completely Resected Stage IIB or IIC Melanoma Ruchika Sharma23 Aug 2023 11:23 AM ISTPrinceton: Bristol Myers Squibb has announced that the European Commission (EC) has approved Opdivo (nivolumab) as a monotherapy for the...
Bristol Myers Squibb gets positive CHMP opinion recommending nod for Opdivo for adjuvant treatment for Melanoma Ruchika Sharma24 July 2023 11:22 AM ISTPrinceton: Bristol Myers Squibb has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency...
Bristol Myers Squibb, Evotec enter licence agreement within neuroscience partnership Ruchika Sharma16 July 2023 11:30 AM ISTEvotec receives a $ 40 m payment and is eligible to earn performance milestone payments, as well as tiered royalties up to low double-digit...
Bristol Myers Squibb bags European Commission nod for heart disease treatment Camzyos Ruchika Sharma27 Jun 2023 11:31 AM ISTPrinceton: Bristol Myers Squibb has announced that the European Commission (EC) has approved CAMZYOS (mavacamten, 2.5 mg, 5 mg, 10 mg,...
Bristol Myers Squibb gets USFDA nod for commercial production at newest Devens cell therapy manufacturing facility Ruchika Sharma11 Jun 2023 11:45 AM ISTPrinceton:: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has approved commercial production at the...
Bristol Myers Squibb gets USFDA priority review for lung cancer treatment Repotrectinib Ruchika Sharma1 Jun 2023 2:00 PM ISTNon-small cell lung cancer is one of the most common types of lung cancer, representing up to 84% of diagnoses.
Bristol Myers Squibb receives EMA panel recommendation for approval of Opdivo with chemotherapy for lung cancer patients Ruchika Sharma29 May 2023 11:30 AM ISTOpdivo is a programmed death-1 immune checkpoint inhibitor that is designed to uniquely harness the body's own immune system to help restore...
Janssen Milvexian gets USFDA fast track designation for Ischemic Stroke, Acute Coronary Syndrome, Atrial Fibrillation Ruchika Sharma26 May 2023 3:15 PM ISTRaritan: The Janssen Pharmaceutical Companies of Johnson & Johnson has announced that all three prospective indications for milvexian, an ...
Amphista Therapeutics achieves first discovery milestone in collaboration with Bristol Myers Squibb Ruchika Sharma7 May 2023 10:00 AM ISTCambridge: Amphista Therapeutics has announced the delivery of the first discovery milestone under its collaboration and license agreement with...
Bristol Myers Squibb gets European Commission nod for CAR T Cell therapy Breyanzi for relapsed or refractory large B-cell lymphoma after one prior therapy Ruchika Sharma5 May 2023 2:30 PM ISTBreyanzi is a CD19-directed CAR T cell therapy with a 4-1BB costimulatory domain, which enhances the expansion and persistence of the CAR T cells.
